Makers of Zantac stopping distribution due to cancer concerns

OTTAWA – The maker of a popular heartburn medication is halting distribution amid concerns of a cancer-causing chemical.

Sandoz, the makers of Zantac made the decision days after regulators in the U.S. and Europe found NDMA, a known carcinogen, in the medications.

The chemical was found in brand name and generic forms of Zantac, which the key ingredient is Ranitidine.

The company also issued a recall for Canada for the following products: Sandoz Ranitidine 150 mg tablet and 300 mg tablet.

Health Canada is also asking all companies to stop distribution of the medicine.

Top Stories

Top Stories

Most Watched Today